Biotech Analysts discuss Friedreich Ataxia (FA) Pathology and expectations for Design Therapeutics (DSGN) DT-216 on an Analyst/Industry conference call to be held on November 10.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DSGN:
- Piper Sandler biotech analysts to hold an analyst/industry conference call
- Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022
- Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit